An important research article published on “Unknown Health
Risks of Inhalation Insulin” By T. R. Shantha, MD, PhD, FACA, Life Extension, September 2007 issue in USA.
This publication played a role in Pfizer withdrawing it Inhalation Insulin named Exubera, from the market in October
2007. Pfizer Pharmaceutical Company took a loss of 2.5 billion dollars. But, this action saved thousands
of people developing cancers of respiratory, and oro – naso - pharyngeal system by its prolonged use with increase in
Asthma etc; and future litigations amounting to billions by users. Received a letter from Glaxo Smith Kline
Company supporting Dr. T. R. Shantha’s article. The drug companies will revise all inhalation insulin research in the
light my recent research article. The copy of the letter from Glaxo is attached. I have sent my research
article FDA offices and many drug companies which are trying to develop this dangerous mode of administration of Insulin.